Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis
To compare the efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B. The Web of Science, PubMed, Cochrane Library, EMBASE, Clinical Trials and China National Knowledge Infrastructure(CNKI) databases were electronically searched to collect randomized controlled tria...
Gespeichert in:
| Veröffentlicht in: | PloS one 2019-11, Vol.14 (11), p.e0224773-e0224773 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0224773 |
|---|---|
| container_issue | 11 |
| container_start_page | e0224773 |
| container_title | PloS one |
| container_volume | 14 |
| creator | Chen, Mao-Bing Wang, Hua Zheng, Qi-Han Zheng, Xu-Wen Fan, Jin-Nuo Ding, Yun-Long Niu, Jia-Li |
| description | To compare the efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B.
The Web of Science, PubMed, Cochrane Library, EMBASE, Clinical Trials and China National Knowledge Infrastructure(CNKI) databases were electronically searched to collect randomized controlled trials (RCTs) regarding the comparison between tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B (CHB) since the date of database inception to July 2019. Two researchers independently screened and evaluated the obtained studies and extracted the outcome indexes. RevMan 5.3 software was used for the meta-analysis.
Early on, tenofovir had a greater ability to inhibit the hepatitis B virus, I2 = 0% [RR = 1.08, 95% CI (1.03, 1.13), P |
| doi_str_mv | 10.1371/journal.pone.0224773 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_plos_</sourceid><recordid>TN_cdi_plos_journals_2316786171</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_4547fe54491440c3a5bf9bdf64c4a840</doaj_id><sourcerecordid>2316786171</sourcerecordid><originalsourceid>FETCH-LOGICAL-c526t-2b94a6a2fa7f8bfdbf47784846025d398fb9692b38ef94ca13eac7d59d80a6853</originalsourceid><addsrcrecordid>eNptkk1v1DAQhiMEoqXwDxBE4lIOWeKP2E4PSGXFR6VKXOBsTZzxrleJvdjJov0L_Gqyu2nVIk62Z955PO9osuw1KReESfJhE8booVtsg8dFSSmXkj3JzknNaCFoyZ4-uJ9lL1LalGXFlBDPszNGZEWYEOfZn2XotxBhcDvM0VpnwOzzYPMBfbBh52IOvs3RD2jg8HI-96PpMKTL4b1rcUpDF1YjFh4ODLOOwTuTr3E7QQeX8k9X-XWe9mnAfoqYPOLO4e8jtscBigNgn1x6mT2z0CV8NZ8X2c8vn38svxW337_eLK9vC1NRMRS0qTkIoBakVY1tGzs5V1xxUdKqZbWyTS1q2jCFtuYGCEMwsq3qVpUgVMUusrcn7rYLSc9jTJoyIqQSRJJJcXNStAE2ehtdD3GvAzh9DIS40hAnKx1qXnFpseK8JpyXhkHV2LppreCGg-LlxPo4_zY2PbZmmmSE7hH0cca7tV6FnRZKUsLZBLicATH8GjENunfJYNeBxzAe-5aVYqquJ-m7f6T_d8dPKhNDShHtfTOk1IfVuqvSh9XS82pNZW8eGrkvutsl9hfMks87</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2316786171</pqid></control><display><type>article</type><title>Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Chen, Mao-Bing ; Wang, Hua ; Zheng, Qi-Han ; Zheng, Xu-Wen ; Fan, Jin-Nuo ; Ding, Yun-Long ; Niu, Jia-Li</creator><contributor>Kim, Seung Up</contributor><creatorcontrib>Chen, Mao-Bing ; Wang, Hua ; Zheng, Qi-Han ; Zheng, Xu-Wen ; Fan, Jin-Nuo ; Ding, Yun-Long ; Niu, Jia-Li ; Kim, Seung Up</creatorcontrib><description>To compare the efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B.
The Web of Science, PubMed, Cochrane Library, EMBASE, Clinical Trials and China National Knowledge Infrastructure(CNKI) databases were electronically searched to collect randomized controlled trials (RCTs) regarding the comparison between tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B (CHB) since the date of database inception to July 2019. Two researchers independently screened and evaluated the obtained studies and extracted the outcome indexes. RevMan 5.3 software was used for the meta-analysis.
Early on, tenofovir had a greater ability to inhibit the hepatitis B virus, I2 = 0% [RR = 1.08, 95% CI (1.03, 1.13), P<0.01] (96 weeks). Entecavir can normalize the ALT levels earlier, I2 = 0% [RR = 0.87, 95% CI (0.77, 0.98), P = 0.02] (48 weeks). However, there was no statistically significant difference between TDF and ETV at 144 weeks. Tenofovir was as effective as entecavir in terms of HBeAg clearance and HBeAg seroconversion, I2 = 0% [RR = 1.05, 95% CI (0.68, 1.62), P = 0.82]; I2 = 69% [RR = 0.93, 95% CI (0.54, 1.61), P = 0.80]. The difference in the incidence of elevated creatine kinase levels was not statistically significant I2 = 0% [RR = 0.66, 95% CI (0.27, 1.60), P = 0.35].
Tenofovir and entecavir were equally effective in the treatment of patients with nucleos(t)ide analogue-naive chronic hepatitis B. In addition, TDF has an advantage in the incidence of hepatocellular carcinoma. Additional RCTs and a large-sample prospective cohort study should be performed.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0224773</identifier><identifier>PMID: 31751366</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Antigens ; Antiretroviral drugs ; Antiviral Agents - therapeutic use ; Antiviral drugs ; Biology and life sciences ; Carcinoma, Hepatocellular - epidemiology ; Carcinoma, Hepatocellular - prevention & control ; Carcinoma, Hepatocellular - virology ; Clinical trials ; Creatine ; Creatine kinase ; Drug resistance ; Guanine - analogs & derivatives ; Guanine - therapeutic use ; Hepatitis ; Hepatitis B ; Hepatitis B e antigen ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - pathology ; Hepatitis B, Chronic - virology ; Hepatocellular carcinoma ; Hospitals ; Humans ; Incidence ; Infections ; Interferon ; Kinases ; Liver cancer ; Liver Neoplasms - epidemiology ; Liver Neoplasms - prevention & control ; Liver Neoplasms - virology ; Medicine ; Medicine and health sciences ; Meta-analysis ; Physical Sciences ; Randomized Controlled Trials as Topic ; Research and Analysis Methods ; Seroconversion ; Statistical analysis ; Statistical significance ; Systematic review ; Tenofovir ; Tenofovir - therapeutic use ; Treatment Outcome ; Viruses</subject><ispartof>PloS one, 2019-11, Vol.14 (11), p.e0224773-e0224773</ispartof><rights>2019 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 Chen et al 2019 Chen et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c526t-2b94a6a2fa7f8bfdbf47784846025d398fb9692b38ef94ca13eac7d59d80a6853</citedby><cites>FETCH-LOGICAL-c526t-2b94a6a2fa7f8bfdbf47784846025d398fb9692b38ef94ca13eac7d59d80a6853</cites><orcidid>0000-0001-5037-9870</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872143/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872143/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79343,79344</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31751366$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Kim, Seung Up</contributor><creatorcontrib>Chen, Mao-Bing</creatorcontrib><creatorcontrib>Wang, Hua</creatorcontrib><creatorcontrib>Zheng, Qi-Han</creatorcontrib><creatorcontrib>Zheng, Xu-Wen</creatorcontrib><creatorcontrib>Fan, Jin-Nuo</creatorcontrib><creatorcontrib>Ding, Yun-Long</creatorcontrib><creatorcontrib>Niu, Jia-Li</creatorcontrib><title>Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>To compare the efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B.
The Web of Science, PubMed, Cochrane Library, EMBASE, Clinical Trials and China National Knowledge Infrastructure(CNKI) databases were electronically searched to collect randomized controlled trials (RCTs) regarding the comparison between tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B (CHB) since the date of database inception to July 2019. Two researchers independently screened and evaluated the obtained studies and extracted the outcome indexes. RevMan 5.3 software was used for the meta-analysis.
Early on, tenofovir had a greater ability to inhibit the hepatitis B virus, I2 = 0% [RR = 1.08, 95% CI (1.03, 1.13), P<0.01] (96 weeks). Entecavir can normalize the ALT levels earlier, I2 = 0% [RR = 0.87, 95% CI (0.77, 0.98), P = 0.02] (48 weeks). However, there was no statistically significant difference between TDF and ETV at 144 weeks. Tenofovir was as effective as entecavir in terms of HBeAg clearance and HBeAg seroconversion, I2 = 0% [RR = 1.05, 95% CI (0.68, 1.62), P = 0.82]; I2 = 69% [RR = 0.93, 95% CI (0.54, 1.61), P = 0.80]. The difference in the incidence of elevated creatine kinase levels was not statistically significant I2 = 0% [RR = 0.66, 95% CI (0.27, 1.60), P = 0.35].
Tenofovir and entecavir were equally effective in the treatment of patients with nucleos(t)ide analogue-naive chronic hepatitis B. In addition, TDF has an advantage in the incidence of hepatocellular carcinoma. Additional RCTs and a large-sample prospective cohort study should be performed.</description><subject>Antigens</subject><subject>Antiretroviral drugs</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antiviral drugs</subject><subject>Biology and life sciences</subject><subject>Carcinoma, Hepatocellular - epidemiology</subject><subject>Carcinoma, Hepatocellular - prevention & control</subject><subject>Carcinoma, Hepatocellular - virology</subject><subject>Clinical trials</subject><subject>Creatine</subject><subject>Creatine kinase</subject><subject>Drug resistance</subject><subject>Guanine - analogs & derivatives</subject><subject>Guanine - therapeutic use</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B e antigen</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - pathology</subject><subject>Hepatitis B, Chronic - virology</subject><subject>Hepatocellular carcinoma</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infections</subject><subject>Interferon</subject><subject>Kinases</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - epidemiology</subject><subject>Liver Neoplasms - prevention & control</subject><subject>Liver Neoplasms - virology</subject><subject>Medicine</subject><subject>Medicine and health sciences</subject><subject>Meta-analysis</subject><subject>Physical Sciences</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Research and Analysis Methods</subject><subject>Seroconversion</subject><subject>Statistical analysis</subject><subject>Statistical significance</subject><subject>Systematic review</subject><subject>Tenofovir</subject><subject>Tenofovir - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Viruses</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNptkk1v1DAQhiMEoqXwDxBE4lIOWeKP2E4PSGXFR6VKXOBsTZzxrleJvdjJov0L_Gqyu2nVIk62Z955PO9osuw1KReESfJhE8booVtsg8dFSSmXkj3JzknNaCFoyZ4-uJ9lL1LalGXFlBDPszNGZEWYEOfZn2XotxBhcDvM0VpnwOzzYPMBfbBh52IOvs3RD2jg8HI-96PpMKTL4b1rcUpDF1YjFh4ODLOOwTuTr3E7QQeX8k9X-XWe9mnAfoqYPOLO4e8jtscBigNgn1x6mT2z0CV8NZ8X2c8vn38svxW337_eLK9vC1NRMRS0qTkIoBakVY1tGzs5V1xxUdKqZbWyTS1q2jCFtuYGCEMwsq3qVpUgVMUusrcn7rYLSc9jTJoyIqQSRJJJcXNStAE2ehtdD3GvAzh9DIS40hAnKx1qXnFpseK8JpyXhkHV2LppreCGg-LlxPo4_zY2PbZmmmSE7hH0cca7tV6FnRZKUsLZBLicATH8GjENunfJYNeBxzAe-5aVYqquJ-m7f6T_d8dPKhNDShHtfTOk1IfVuqvSh9XS82pNZW8eGrkvutsl9hfMks87</recordid><startdate>20191121</startdate><enddate>20191121</enddate><creator>Chen, Mao-Bing</creator><creator>Wang, Hua</creator><creator>Zheng, Qi-Han</creator><creator>Zheng, Xu-Wen</creator><creator>Fan, Jin-Nuo</creator><creator>Ding, Yun-Long</creator><creator>Niu, Jia-Li</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-5037-9870</orcidid></search><sort><creationdate>20191121</creationdate><title>Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis</title><author>Chen, Mao-Bing ; Wang, Hua ; Zheng, Qi-Han ; Zheng, Xu-Wen ; Fan, Jin-Nuo ; Ding, Yun-Long ; Niu, Jia-Li</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c526t-2b94a6a2fa7f8bfdbf47784846025d398fb9692b38ef94ca13eac7d59d80a6853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antigens</topic><topic>Antiretroviral drugs</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antiviral drugs</topic><topic>Biology and life sciences</topic><topic>Carcinoma, Hepatocellular - epidemiology</topic><topic>Carcinoma, Hepatocellular - prevention & control</topic><topic>Carcinoma, Hepatocellular - virology</topic><topic>Clinical trials</topic><topic>Creatine</topic><topic>Creatine kinase</topic><topic>Drug resistance</topic><topic>Guanine - analogs & derivatives</topic><topic>Guanine - therapeutic use</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B e antigen</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - pathology</topic><topic>Hepatitis B, Chronic - virology</topic><topic>Hepatocellular carcinoma</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infections</topic><topic>Interferon</topic><topic>Kinases</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - epidemiology</topic><topic>Liver Neoplasms - prevention & control</topic><topic>Liver Neoplasms - virology</topic><topic>Medicine</topic><topic>Medicine and health sciences</topic><topic>Meta-analysis</topic><topic>Physical Sciences</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Research and Analysis Methods</topic><topic>Seroconversion</topic><topic>Statistical analysis</topic><topic>Statistical significance</topic><topic>Systematic review</topic><topic>Tenofovir</topic><topic>Tenofovir - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Mao-Bing</creatorcontrib><creatorcontrib>Wang, Hua</creatorcontrib><creatorcontrib>Zheng, Qi-Han</creatorcontrib><creatorcontrib>Zheng, Xu-Wen</creatorcontrib><creatorcontrib>Fan, Jin-Nuo</creatorcontrib><creatorcontrib>Ding, Yun-Long</creatorcontrib><creatorcontrib>Niu, Jia-Li</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Mao-Bing</au><au>Wang, Hua</au><au>Zheng, Qi-Han</au><au>Zheng, Xu-Wen</au><au>Fan, Jin-Nuo</au><au>Ding, Yun-Long</au><au>Niu, Jia-Li</au><au>Kim, Seung Up</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2019-11-21</date><risdate>2019</risdate><volume>14</volume><issue>11</issue><spage>e0224773</spage><epage>e0224773</epage><pages>e0224773-e0224773</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>To compare the efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B.
The Web of Science, PubMed, Cochrane Library, EMBASE, Clinical Trials and China National Knowledge Infrastructure(CNKI) databases were electronically searched to collect randomized controlled trials (RCTs) regarding the comparison between tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B (CHB) since the date of database inception to July 2019. Two researchers independently screened and evaluated the obtained studies and extracted the outcome indexes. RevMan 5.3 software was used for the meta-analysis.
Early on, tenofovir had a greater ability to inhibit the hepatitis B virus, I2 = 0% [RR = 1.08, 95% CI (1.03, 1.13), P<0.01] (96 weeks). Entecavir can normalize the ALT levels earlier, I2 = 0% [RR = 0.87, 95% CI (0.77, 0.98), P = 0.02] (48 weeks). However, there was no statistically significant difference between TDF and ETV at 144 weeks. Tenofovir was as effective as entecavir in terms of HBeAg clearance and HBeAg seroconversion, I2 = 0% [RR = 1.05, 95% CI (0.68, 1.62), P = 0.82]; I2 = 69% [RR = 0.93, 95% CI (0.54, 1.61), P = 0.80]. The difference in the incidence of elevated creatine kinase levels was not statistically significant I2 = 0% [RR = 0.66, 95% CI (0.27, 1.60), P = 0.35].
Tenofovir and entecavir were equally effective in the treatment of patients with nucleos(t)ide analogue-naive chronic hepatitis B. In addition, TDF has an advantage in the incidence of hepatocellular carcinoma. Additional RCTs and a large-sample prospective cohort study should be performed.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>31751366</pmid><doi>10.1371/journal.pone.0224773</doi><orcidid>https://orcid.org/0000-0001-5037-9870</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2019-11, Vol.14 (11), p.e0224773-e0224773 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2316786171 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Antigens Antiretroviral drugs Antiviral Agents - therapeutic use Antiviral drugs Biology and life sciences Carcinoma, Hepatocellular - epidemiology Carcinoma, Hepatocellular - prevention & control Carcinoma, Hepatocellular - virology Clinical trials Creatine Creatine kinase Drug resistance Guanine - analogs & derivatives Guanine - therapeutic use Hepatitis Hepatitis B Hepatitis B e antigen Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - pathology Hepatitis B, Chronic - virology Hepatocellular carcinoma Hospitals Humans Incidence Infections Interferon Kinases Liver cancer Liver Neoplasms - epidemiology Liver Neoplasms - prevention & control Liver Neoplasms - virology Medicine Medicine and health sciences Meta-analysis Physical Sciences Randomized Controlled Trials as Topic Research and Analysis Methods Seroconversion Statistical analysis Statistical significance Systematic review Tenofovir Tenofovir - therapeutic use Treatment Outcome Viruses |
| title | Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T13%3A10%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20efficacy%20of%20tenofovir%20and%20entecavir%20in%20nucleos(t)ide%20analogue-naive%20chronic%20hepatitis%20B:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=PloS%20one&rft.au=Chen,%20Mao-Bing&rft.date=2019-11-21&rft.volume=14&rft.issue=11&rft.spage=e0224773&rft.epage=e0224773&rft.pages=e0224773-e0224773&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0224773&rft_dat=%3Cproquest_plos_%3E2316786171%3C/proquest_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2316786171&rft_id=info:pmid/31751366&rft_doaj_id=oai_doaj_org_article_4547fe54491440c3a5bf9bdf64c4a840&rfr_iscdi=true |